Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study

Jui-Ting Mao 1,†, Jung-Nien Lai 2,3,†, Yi-Hsiu Fu 4,†, Hei-Tung Yip 5, Yen-Chun Lai 6, Chung-Y. Hsu 7, Sung-Hsiung Chen 8,9, and Shu-Jui Kuo 1,9,*

1 Department of Orthopedic Surgery, China Medical University Hospital, Taichung 404, Taiwan
2 Department of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan
3 School of Chinese Medicine, China Medical University, Taichung 404, Taiwan
4 Department of Education, Taichung Veterans General Hospital, Taichung 407, Taiwan
5 Management office for Health Data, China Medical University Hospital, Taichung 404, Taiwan
6 School of Medicine, National Taiwan University, Taipei 100, Taiwan
7 Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
8 Department of Orthopedic Surgery, College of Medicine, Chang Gung University, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
9 School of Medicine, China Medical University, Taichung 404, Taiwan
* Correspondence: chensh@cgmh.org.tw (S.-H.C.); b90401073@gmail.com (S.-J.K.)
† These authors contributed equally to this work.

Abstract: Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occurrence of hip fracture among T2DM patients. We chose the patients newly diagnosed with T2DM and divided them into four subgroups which are under aspirin monotherapy (78,522 patients), clopidogrel monotherapy (12,752 patients), dual therapy (7209 patients), and patients not taking antiplatelet drugs (401,686 patients). We found that only higher dosage (>360 cumulative daily defined dose (cDDD)) and longer duration (≥3 years) of antiplatelet agents could be associated with lower fracture risk. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 0.38-fold for the patients taking ≥3-year dual agents. Lower dosage (28–179 cDDD) and shorter duration (1~2 years) could even be associated with higher fracture risk. Overall, the best regimen to fend off the hip fracture was the use of aspirin and clopidogrel for ≥3 years.

Keywords: aspirin; clopidogrel; hip fracture; type 2 diabetes

1. Introduction

The rising prevalence of type 2 diabetes mellitus (T2DM) is an important public health issue [1]. The number of DM patients worldwide has doubled in the past thirty years. T2DM is associated with higher risk of thromboembolic diseases, such as coronary artery disease and cerebrovascular disease. The risk of hip fracture is also higher among T2DM patients [2]. Thromboembolic diseases and hip fracture are potentially fatal, and the therapies that can treat and prevent these potentially fatal morbidities among T2DM patients are a major field worthy of discussion.

Antiplatelet drugs are widely used in the treatment and prevention of thromboembolic diseases among T2DM patients. Aspirin is an inhibitor of prostaglandin synthesis and may impact bone remodeling [3]. Clopidogrel is a thienopyridine and inhibits platelet function by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor, which are involved in the regulation of metabolic activities of bone cells [4,5]. Aspirin and clopidogrel are commonly prescribed alone or together for T2DM patients, and, interestingly, both...
agents could affect bone metabolism. It is thus an interesting issue that whether these two agents could affect the risk of hip fracture, another T2DM-related fatal morbidity other than thromboembolic diseases, among T2DM patients.

Osteoporosis is a prevalent disease in the aging society, and the gravest complication associated with osteoporosis is hip fracture. Hip fractures account for one-fourth of geriatric fractures necessitating hospitalization with the mortality rate reaching 20% [6–10]. T2DM patients are prone to suffer from higher risk of hip fracture, death after fracture, and hip fracture-free mortality. T2DM males and females are at 28% and 57% excessive risk of mortality after suffering from hip fracture, respectively [2]. In fact, the impact of aspirin and clopidogrel, as a single agent, on the occurrence of hip fracture for the general population has been discussed in the previous literature, and the results vary substantially across different studies due to coarse stratification of dosage and duration [11]. The effects of combination of the two agents on fracture risk have not been explored.

In view of the limitations of current publications, we conducted a population-based study to investigate the impact of aspirin and/or clopidogrel with detailed stratification of dosage and duration on the risk of hip fracture among T2DM patients. The effects of combination therapy were also determined. We also investigated the risk of hemorrhagic stroke among the T2DM patients under antiplatelet therapy. We hypothesize that antiplatelet agents could affect the risk of hip fracture among T2DM patients.

2. Materials and Methods

2.1. Data Source

Taiwan National Health Insurance Research Database (NHIRD) contains medical data of around 23 million residents. We utilized the dataset of Longitudinal Cohort of Diabetes Patients for this cohort study. The dataset contains the medical record of inpatient/outpatient records of disease diagnosis, drug prescriptions or therapy, which was coded using the International Classification of Diseases Clinical Modification, 9th Revision (ICD-9 CM). This study was approved by the Institutional Review Board of China Medical University Hospital Research Ethics Committee (CMUH104-REC2-115(AR-4)). Patient consent was waived under the agreement of the Committee because the identity of the subjects could not be identified.

2.2. Patient Population

We selected the patients who were newly diagnosed with T2DM within 2000 to 2012 as the study population. These T2DM were then divided into antiplatelet users (including aspirin monotherapy, clopidogrel monotherapy, and dual therapy) and antiplatelet non-users. The first prescription date was the index date for the antiplatelet users and a random date between 2000 and 2012 was set as the index date for the non-users. The exclusion criteria were hip fracture occurred before the index date, missing information of sex, previous use of anti-resorptive or anabolic agents for osteoporosis, and age below 18. All the antiplatelet users were propensity-score matched by four T2DM non-users. Finally, there were 78,522 patients under aspirin monotherapy, 12,752 patients under clopidogrel monotherapy and 7209 patients under dual therapy. The 401,686 T2DM patients without the use of antiplatelet agents were assigned to control group.

2.3. Main Outcome and Covariates

The risk of hip fracture (ICD-9-CM code 820, A473) was the outcome of interest in our study. Comorbidities included hypertension (ICD-9-CM code 401–405, A260, A269), hyperlipidemia (ICD-9-CM code 272), coronary artery disease (CAD) (ICD-9-CM code 410–414, A270, A279), stroke (ICD-9-CM code 430–438), arrhythmia (ICD-9-CM code 427), chronic kidney disease (CKD) (ICD-9-CM code 585), chronic obstructive pulmonary disease (COPD) (ICD-9-CM code 490–492, 496), and osteoporosis (ICD-9-CM code 733.0). Charlson Comorbidity Index (CCIs) and adapted Diabetes Complication Severity Index (aDSCI) were employed to evaluate the seriousness of diabetes mellitus patients. Antidiabetic drugs,
antihypertensive drugs, statins, non-steroidal anti-inflammatory drug (NSAIDs), and oral steroids were also included as covariates in our model.

2.4. Statistical Analysis

The between-group differences were shown as standardized mean difference (SMD). The SMD method has been employed to estimate the similarity of baseline characteristics in propensity-score-matched cohorts. An SMD < 0.10 indicates a negligible imbalance between study individuals and their matched controls [12]. Cox proportional hazards models were applied to assess the hazard ratio (HR) and unravel the correlation between the exposure to antiplatelet agents and hip fracture [13,14]. A multivariate Cox proportional hazards model was utilized to assess the adjusted HRs (aHRs) after adjustment for age, sex, comorbidities, medications, CCIs, and aDCSI. An analysis of stratification by age, sex, CCIs, and aDCSI was implemented to assess the correlation between exposure to antiplatelet agents and hip fracture among the cohort of interest. Subhazard ratios (SHRs) were calculated employing competing risk regression models, considering death as the competing risk factor. The cumulative incidence of hip fracture was expressed by the Kaplan–Meier method, and a log-rank test was applied for the comparison of the incidence curves [12]. All statistical analyses were carried out applying STATA/SE software (version 14.0, STATA Corp., College Station, TX, USA). Two-tailed tests were applied to assess the statistical significance (p < 0.05).

3. Results

There were 78,522 patients under aspirin monotherapy, 12,752 patients under clopidogrel monotherapy, and 7209 patients under dual therapy. The 401,686 individuals without the use of antiplatelet agents were assigned to control group. The distributions of the comorbidities among the four groups were comparable under the propensity score matching. The score of baseline CCI and baseline aDSCI as well as the medicine taken by the participants were also comparable between the four group (all SMD < 0.10) (Table 1).

Table 1. Baseline characteristics of the four cohorts.

| Variables       | Antiplatelet Non-User (N = 401,686) | Antiplatelet Users (N = 98,483) |
|-----------------|------------------------------------|---------------------------------|
|                 |      |    |      |    |    |                  |      |    |                  |
|                 | n    | %  | n    | %  | n    | %  | n    | %  | SMD   |
| Sex             |      |    |      |    |      |    |      |    |       |
| Female          | 192,615 | 48% | 39,691 | 51% | 3766 | 30% | 2056 | 29% | 0.035 |
| Male            | 209,071 | 52% | 38,831 | 49% | 8986 | 70% | 5153 | 71% |       |
| Age, year       |      |    |      |    |      |    |      |    | 0.064 |
| <30             | 9487  | 2.4% | 1850  | 2.4% | 16   | 0.1% | 13   | 0.2% |       |
| 30–50           | 95,811 | 24% | 20,986 | 27% | 1574 | 12% | 1241 | 17% |       |
| 50–70           | 217,461 | 54% | 44,284 | 56% | 6981 | 55% | 4176 | 58% |       |
| ≥70             | 78,927 | 20% | 11,402 | 15% | 4181 | 33% | 1779 | 25% |       |
| Mean (SD)       | 58.1 (13.6) |      | 56.4 (12.6) |      | 64.1 (12.1) |      | 61.2 (12.0) |      | 0.025 |
| Comorbidities   |      |    |      |    |      |    |      |    |       |
| Hypertension    | 258,897 | 64% | 46,129 | 59% | 10,484 | 82% | 5314 | 74% | 0.033 |
| Hyperlipidemia  | 258,217 | 64% | 48,601 | 62% | 8729  | 68% | 4578 | 64% | 0.030 |
| CAD             | 104,214 | 26% | 15,162 | 19% | 6303  | 51% | 2356 | 35% | 0.031 |
| Stroke          | 51,94  | 1%  | 617   | 1%  | 694   | 5%  | 161  | 2%  | 0.017 |
| Arrhythmia      | 54,806 | 14% | 8963  | 11% | 2669  | 21% | 1136 | 16% | 0.020 |
| CKD             | 15,657 | 4%  | 2317  | 3%  | 1400  | 11% | 529  | 7%  | 0.021 |
| COPD            | 77,572 | 19% | 14,062 | 18% | 3162  | 25% | 1570 | 22% | 0.006 |
| Osteoporosis    | 2162  | 1%  | 428   | 1%  | 62    | 0.5% | 28   | 0.4% | 0.002 |
Table 1. Cont.

| Variables       | Antiplatelet Non-User (N = 401,686) | Antiplatelet Users (N = 98,483) |       |
|-----------------|-------------------------------------|---------------------------------|-------|
|                 |                                     | Aspirin Monotherapy             | Clopidogrel Mono Therapy | Dual Therapy |
|                 |                                     | N = 78,522                      | N = 12,752                 | N = 7209    |
|                 |                                     | n (%)                           | n (%)                      | n (%)       | n (%)       | SMD |
| CCIs            |                                     | 0                               | 249,662 62%                | 51,785 66% | 3162 25%    | 2873 40% | 0.081 |
|                 |                                     | 1                               | 61,021 15%                 | 11,571 15% | 3851 30%    | 2042 28% |
|                 |                                     | ≥3                              | 46,872 12%                 | 8194 10%   | 2327 18%    | 1033 14% |
| aDCSI           |                                     | 0                               | 44,131 11%                 | 6972 9%    | 3412 27%    | 1261 17% | 0.049 |
| Medications     |                                     | 1                               | 333,706 83%                | 66,690 85% | 8018 63%    | 5502 76% |
| Anti-DM drugs   |                                     | ≥2                              | 34,738 9%                  | 7112 9%    | 1943 15%    | 794 11%  |
| Metformin       |                                     |                                 | 32,422 8%                  | 4720 6%    | 2791 22%    | 913 13%  |
| Sulfonyluracils |                                     |                                 | 213,265 53%                | 40,974 52% | 7915 62%    | 4278 59% |
| α-glucosidase inhibitors |               | 184,031 46%                     | 35,903 46%                 | 6960 55%   | 3956 55%    | 0.035     |
| Thiazolidinedione |                               | 39,287 10%                      | 7361 9%                    | 1973 15%   | 798 11%     | 0.017     |
| Insulin         |                                     |                                 | 35,793 9%                  | 7027 9%    | 1658 13%    | 752 10%  |
| Anti-HTN drugs  |                                     |                                 | 37,023 9%                  | 6761 9%    | 2573 20%    | 1258 17% |
| α-blockers      |                                     |                                 | 73,503 18%                 | 12,196 16% | 4045 32%    | 1839 26% |
| β-blockers      |                                     |                                 | 211,920 53%                | 37,258 47% | 8615 68%    | 4192 58% |
| Potassium-sparing diuretics |       | 18,825 5%                       | 3285 4%                    | 1065 8%    | 496 7%      | 0.011     |
| Thiazides diuretics |                                | 35,793 9%                       | 7027 9%                    | 1658 13%   | 752 10%     | 0.023     |
| Loop diuretics  |                                     | 77,655 19%                      | 13,436 17%                 | 3857 30%   | 1818 25%    | 0.002     |
| CCBs            |                                     | 212,199 53%                     | 36,608 47%                 | 9132 72%   | 4552 63%    | 0.035     |
| ACEIs           |                                     | 183,404 46%                     | 30,943 39%                 | 8462 66%   | 4073 56%    | 0.030     |
| ARBs            |                                     | 88,513 22%                      | 14,865 19%                 | 4590 36%   | 2044 28%    | 0.005     |
| Statins         |                                     | 161,715 40%                     | 28,131 36%                 | 7097 56%   | 3155 44%    | 0.026     |
| NSAIDs          |                                     | 389,629 97%                     | 76,153 97%                 | 12,095 95% | 6827 95%    | 0.026     |
| Oral steroid    |                                     | 312,091 78%                     | 61,695 79%                 | 9180 72%   | 5078 70%    | 0.014     |

SMD: standard mean difference; CAD: coronary artery disease; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; HTN: hypertension; CCIs: Charlton comorbidity index; aDCSI: adapted diabetes complication severity index; CCBs: calcium channel blockers; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; NSAIDs: non-steroidal anti-inflammatory drug.

Table 2 demonstrates the incidence of hip fracture stratified by dosage and duration of the use of antiplatelet agents. The risk of hip fracture among the patients taking 28–179 cumulative daily defined dose (cDDD) aspirin was 1.13-fold (aHR: 1.01~1.25) than that of the patients taking <28 cDDD aspirin. Compared with the subjects taking <28 cDDD clopidogrel, the risk of hip fracture was 1.39-fold (aHR: 1.10~1.75) and 0.51-fold (aHR: 0.37~0.72) for the patients taking 28–179 cDDD and ≥360 cDDD clopidogrel, respectively. Compared with the subjects taking <28 cDDD dual agents, the risk of hip fracture was 1.18-fold (aHR: 1.06~1.30) and 0.74-fold (aHR: 0.61~0.91) for the patients taking 28–179 cDDD and ≥360 cDDD dual agents, respectively. Compared with the subjects taking <1-year aspirin, the risk of hip fracture was 2.54-fold (aHR: 2.14~3.02) and 0.42-fold (aHR: 0.35~0.49) for the patients taking 1–2 year and ≥3-year aspirin, respectively. Compared with the subjects taking <1-year clopidogrel, the risk of hip fracture was 0.52-fold (aHR: 0.33~0.80) for the patients taking 2–3-year clopidogrel. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 1.97-fold (aHR: 1.68~2.30) and 0.38-fold (aHR: 0.33~0.45) for the patients taking 1–2 year and ≥3-year dual agents, respectively. The cumulative
incidence curves of hip fracture stratified by cDDD and duration for the patients taking aspirin, clopidogrel, and dual agents were illustrated in Figures 1 and 2. The cumulative incidence of hip fracture varied significantly among different cDDD-based stratification in the aspirin monotherapy group ($p < 0.001$ by log rank test). The cumulative incidence of hip fracture also varied significantly among different duration-based stratification in the aspirin monotherapy group ($p < 0.001$ by log rank test), clopidogrel monotherapy group ($p < 0.001$ by log rank test), and dual therapy group ($p < 0.001$ by log rank test). The fracture risk reduction effects of antiplatelet agents are only present in the higher cDDD and longer duration curves. The Table 2, Figures 1 and 2 showed that antiplatelet agents could only exert protective effects in higher dosage ($\geq 360$ cDDD) and longer duration ($\geq 3$-year) ranges. Lower dosage (28–179 cDDD) and shorter duration (1–2 years) could even be associated with higher risk of hip fracture.

![Figure 1](image1.png)

**Figure 1.** The cumulative incidence of hip fracture among patients with different cumulative defined daily doses (cDDDs) of aspirin (A), clopidogrel (B), and dual anti-platelet agents (C).

![Figure 2](image2.png)

**Figure 2.** The cumulative incidence of hip fracture among patients with different duration (years) of aspirin (A), clopidogrel (B), and dual anti-platelet agents (C).

Table 3 shows the risk of hip fracture stratified by sex, age, CCIs, aDCSI, and the diagnosis of osteoporosis. In general, the impact of antiplatelet agents on hip fracture could not be demonstrated without the stratification of dosage and duration. However, the stratification based on age, CCIs, aDCSI, and the diagnosis of osteoporosis showed that the female T2DM patients undergoing aspirin monotherapy seems to have lower risk of hip fracture than the female T2DM patients without any anti-platelet therapy.
Table 2. Hazard ratio of hip fracture stratified by dosage and duration of antiplatelet agents.

| Variables                      | n     | PY      | IR      | cHR (95% CI) | p-Value | aHR (95% CI) | p-Value |
|-------------------------------|-------|---------|---------|--------------|---------|--------------|---------|
| Hip Fracture                  |       |         |         |              |         |              |         |
| Aspirin or clopidogrel        |       |         |         |              |         |              |         |
| Non-users                     | 2558  | 1,272,862 | 2.01   | 1.00 (reference) | 1.00 (reference) |
| Users                         | 638   | 313,212 | 2.04   | 1.01 (0.92, 1.1) | 0.849 | 1.04 (0.96, 1.14) | 0.338 |
| Aspirin or clopidogrel        |       |         |         |              |         |              |         |
| Non-users                     | 2558  | 1,272,862 | 2.01   | 1.00 (reference) | 1.00 (reference) |
| Aspirin Monotherapy           | 480   | 265,781 | 1.81   | 0.90 (0.82, 0.99) | 0.035 | 1.08 (0.98, 1.20) | 0.111 |
| Clopidogrel Monotherapy       | 101   | 23,862  | 4.23   | 1.95 (1.60, 2.38) | <0.001 | 1.02 (0.83, 1.24) | 0.866 |
| Dual Therapy                  | 57    | 23,568  | 2.42   | 1.19 (0.92, 1.55) | 0.190 | 0.83 (0.63, 1.07) | 0.152 |

Dosage of aspirin (cDDD)

| <28 cDDD                      | 2683  | 1,305,766 | 2.05   | 1.00 (reference) | 1.00 (reference) |
| 28–179 cDDD                   | 395   | 210,415  | 1.88   | 0.91 (0.82, 1.02) | 0.093 | 1.13 (1.01, 1.25) | 0.027 |
| 180–359 cDDD                  | 51    | 32,718   | 1.56   | 0.77 (0.58, 1.01) | 0.063 | 0.84 (0.63, 1.10) | 0.210 |
| ≥360 cDDD                     | 67    | 37,175   | 1.80   | 0.90 (0.7, 1.14)  | 0.372 | 0.94 (0.74, 1.20) | 0.613 |

Dosage of clopidogrel (cDDD)

| <28 cDDD                      | 3049  | 1,542,881 | 1.98   | 1.00 (reference) | 1.00 (reference) |
| 28–179 cDDD                   | 76    | 14,792   | 5.14   | 2.49 (1.98, 3.12) | <0.001 | 1.39 (1.10, 1.75) | 0.005 |
| 180–359 cDDD                  | 37    | 10,991   | 3.37   | 1.61 (1.17, 2.23) | 0.004 | 1.00 (0.73, 1.39) | 0.979 |
| ≥360 cDDD                     | 34    | 17,410   | 1.95   | 0.94 (0.67, 1.32) | 0.734 | 0.51 (0.37, 0.72) | <0.001 |

Dosage of dual agents (cDDD)

| <28 cDDD                      | 2556  | 1,272,011 | 2.01   | 1.00 (reference) | 1.00 (reference) |
| 28–179 cDDD                   | 450   | 217,019  | 2.07   | 1.03 (0.93, 1.13) | 0.610 | 1.18 (1.06, 1.30) | 0.002 |
| 180–359 cDDD                  | 87    | 41,917   | 2.08   | 1.03 (0.83, 1.27) | 0.814 | 0.92 (0.75, 1.15) | 0.475 |
| ≥360 cDDD                     | 103   | 55,127   | 1.87   | 0.93 (0.76, 1.13) | 0.449 | 0.74 (0.61, 0.91) | 0.003 |

Duration of aspirin (year)

| <1                            | 2816  | 1,312,458 | 2.15   | 1.00 (reference) | 1.00 (reference) |
| 1–2                           | 143   | 21,487   | 6.66   | 2.87 (2.42, 3.41) | <0.001 | 2.54 (2.14, 3.02) | <0.001 |
| 2–3                           | 92    | 36,480   | 2.52   | 1.08 (0.88, 1.33) | 0.474 | 1.04 (0.84, 1.28) | 0.739 |
| ≥3                            | 145   | 215,649  | 0.67   | 0.32 (0.27, 0.38) | <0.001 | 0.42 (0.35, 0.49) | <0.001 |

Duration of clopidogrel (year)

| <1                            | 3128  | 1,548,594 | 2.02   | 1.00 (reference) | 1.00 (reference) |
| 1–2                           | 37    | 9014     | 4.10   | 1.84 (1.33, 2.55) | <0.001 | 0.89 (0.64, 1.23) | 0.464 |
| 2–3                           | 20    | 9257     | 2.16   | 0.98 (0.63, 1.52) | 0.918 | 0.52 (0.33, 0.80) | 0.003 |
| ≥3                            | 0     | 0        | 0.00   | -             | -       | -               | -       |

Duration of dual agents (year)

| <1                            | 2753  | 1,280,851 | 2.15   | 1.00 (reference) | 1.00 (reference) |
| 1–2                           | 176   | 27,714   | 6.35   | 2.75 (2.35, 3.22) | <0.001 | 1.97 (1.68, 2.30) | <0.001 |
| 2–3                           | 109   | 43,826   | 2.49   | 1.06 (0.88, 1.29) | 0.533 | 0.88 (0.72, 1.06) | 0.185 |
| ≥3                            | 158   | 233,683  | 0.68   | 0.32 (0.27, 0.38) | <0.001 | 0.38 (0.33, 0.45) | <0.001 |

n: number of event; PY: person-years; IR: incidence rate per 1000 person-years. cHR: crude hazard ratio; aHR: adjusted hazard ratio; CI: confidence interval; cDDD: cumulative defined daily dose; ł: adjusted by sex, age, comorbidities, and medicine.
Table 3. Risk of hip fracture in different subgroups.

| Variables | Non-Users | Aspirin Monotherapy | Clopidogrel Monotherapy | Dual Antiplatelet Therapy |
|-----------|-----------|---------------------|-------------------------|--------------------------|
|           | aHR (95% CI) | p-Value | aHR (95% CI) | p-Value | aHR (95% CI) | p-Value |
| Sex       |            |          |             |          |            |          |
| Female    | 1.00       | 1.21 (1.06, 1.37) | 0.004       | 1.03 (0.77, 1.39) | 0.838       | 0.99 (0.68, 1.43) | 0.958 |
| Male      | 1.00       | 1.05 (0.81, 1.11) | 0.522       | 1.03 (0.78, 1.35) | 0.860       | 0.69 (0.48, 1.01) | 0.057 |
| Age       |            |          |             |          |            |          |
| <30       | 1.00       | 2.09 (0.74, 5.89) | 0.165       |            |            |          |
| 30–50     | 1.00       | 0.92 (0.65, 1.29) | 0.614       | 1.08 (0.39, 2.96) | 0.886       | 0.88 (0.32, 2.38) | 0.798 |
| 50–70     | 1.00       | 1.07 (0.91, 1.24) | 0.412       | 0.91 (0.61, 1.36) | 0.657       | 0.95 (0.64, 1.42) | 0.815 |
| >70       | 1.00       | 1.02 (0.89, 1.17) | 0.777       | 1.11 (0.87, 1.41) | 0.390       | 0.70 (0.87, 1.41) | 0.059 |
| CCI       |            |          |             |          |            |          |
| 0         | 1.00       | 1.14 (0.99, 1.31) | 0.065       | 0.84 (0.47, 1.49) | 0.551       | 0.67 (0.38, 1.18) | 0.165 |
| 1         | 1.00       | 0.97 (0.78, 1.22) | 0.824       | 1.01 (0.66, 1.55) | 0.952       | 1.08 (0.70, 1.65) | 0.735 |
| 2         | 1.00       | 0.94 (0.73, 1.21) | 0.629       | 0.98 (0.63, 1.52) | 0.913       | 0.49 (0.23, 1.04) | 0.064 |
| ≥3        | 1.00       | 1.10 (0.86, 1.40) | 0.439       | 1.11 (0.82, 1.51) | 0.498       | 0.84 (0.51, 1.39) | 0.506 |
| aDCSI     |            |          |             |          |            |          |
| 0         | 1.00       | 1.08 (0.97, 1.20) | 0.177       | 1.02 (0.80, 1.31) | 0.853       | 0.77 (0.57, 1.05) | 0.094 |
| 1         | 1.00       | 1.05 (0.75, 1.48) | 0.770       | 0.80 (0.41, 1.57) | 0.518       | 1.25 (0.62, 2.57) | 0.321 |
| ≥2        | 1.00       | 1.17 (0.81, 1.69) | 0.416       | 1.13 (0.74, 1.73) | 0.577       | 0.85 (0.40, 1.80) | 0.665 |
| Osteoporosis |        |          |             |          |            |          |
| No        | 1.00       | 1.05 (0.95, 1.16) | 0.339       | 1.03 (0.84, 1.26) | 0.781       | 0.82 (0.63, 1.07) | 0.139 |
| Yes       | 1.00       | 0.62 (0.23, 1.67) | 0.544       | 0.84 (0.11, 6.38) | 0.865       |            |          |

cHR: crude hazard ratio; aHR: adjusted hazard ratio; 95% CI: 95% confidence interval; CCI: Charlson comorbidity index; aDCSI: adapted diabetes complication severity index.

After considering death as a competing event, the trend that antiplatelet agents could only exert protective effects against fracture in higher exposure range is similar. Overall, the patients taking dual antiplatelet agents had 0.59-fold (aSHR: 0.42~0.82) the risk of fracture than the non-users. Patients taking 180–359 cDDD clopidogrel (not 28–179 cDDD) had 0.21-fold (aSHR: 0.07~0.66) the risk of fracture than the non-users. Compared with the subjects taking <1-year aspirin, the risk of hip fracture was 8.33-fold (aSHR: 5.31~13.08), 5.09-fold (aSHR: 3.41~7.61), and 0.54-fold (aSHR: 0.44~0.68) for the patients taking 1–2 years, 2–3 years, and ≥3-years aspirin, respectively. Patients taking 1–2 year clopidogrel had 2.06-fold (aSHR: 1.15~3.68) the risk of fracture than the non-users. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 8.07-fold (aSHR: 5.15~12.64), 4.89-fold (aSHR: 3.30~7.24), and 0.50-fold (aSHR: 0.40~0.62) for the patients taking 1–2 years, 2–3 years, and ≥3-years dual agents, respectively (Table 4).

Table 4. Incidence rate and subhazard ratio of hip fracture in patients using antiplatelet agents employing competing risks regression models.

| Variables | cSHR (95% CI) | p-Value | aSHR (95% CI) | p-Value |
|-----------|---------------|---------|---------------|---------|
| Aspirin or clopidogrel |               |         |               |         |
| Non-users | 1.00 (reference) |         | 1.00 (reference) |         |
| Aspirin or clopidogrel |               |         |               |         |
| Non-users | 1.00 (reference) |         | 1.00 (reference) |         |
| Aspirin Monotherapy | 1.67 (1.38, 2.03) | <0.001 | 0.90 (0.73, 1.11) | 0.320 |
| Clopidogrel Monotherapy | 2.68 (1.49, 4.80) | <0.001 | 0.96 (0.53, 1.74) | 0.900 |
| Dual Therapy | 1.58 (1.14, 2.18) | 0.010 | 0.59 (0.42, 0.82) | <0.001 |
| Dose of aspirin |               |         |               |         |
| <28 cDDD | 1.00 (reference) |         | 1.00 (reference) |         |
| 28–179 cDDD | 1.41 (1.12, 1.78) | <0.001 | 0.95 (0.75, 1.21) | 0.660 |
| 180–359 cDDD | 1.58 (1.13, 2.21) | 0.010 | 0.84 (0.60, 1.19) | 0.330 |
| >360 cDDD | 1.70 (1.32, 2.19) | <0.001 | 0.88 (0.67, 1.15) | 0.330 |
### Table 4. Cont.

| Variables                  | cSHR (95% CI)          | p-Value | aSHR (95% CI)          | p-Value |
|----------------------------|------------------------|---------|------------------------|---------|
| **Dose of clopidogrel**    |                        |         |                        |         |
| <28 cDDD                   | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 28–179 cDDD                | 1.90 (1.26, 2.87)      | <0.001  | 0.97 (0.64, 1.47)      | 0.890   |
| 180–359 cDDD               | 0.41 (0.13, 1.27)      | 0.120   | 0.21 (0.07, 0.66)      | 0.010   |
| >360 cDDD                  | 1.42 (0.93, 2.16)      | 0.100   | 0.67 (0.44, 1.03)      | 0.070   |
| **Dose of dual agents**    |                        |         |                        |         |
| <28 cDDD                   | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 28–179 cDDD                | 1.57 (1.24, 1.98)      | <0.001  | 1.00 (0.79, 1.27)      | 0.960   |
| 180–359 cDDD               | 1.58 (1.11, 2.23)      | 0.010   | 0.80 (0.56, 1.14)      | 0.210   |
| >360 cDDD                  | 1.84 (1.45, 2.35)      | <0.001  | 0.83 (0.64, 1.07)      | 0.150   |
| **Duration of aspirin (year)** |                   |         |                        |         |
| <1                         | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 1–2                        | 17.38 (11.13, 27.16)   | <0.001  | 8.33 (5.31, 13.08)     | 0.000   |
| 2–3                        | 10.62 (7.14, 15.81)    | <0.001  | 5.09 (3.41, 7.61)      | 0.000   |
| ≥3                         | 0.94 (0.76, 1.15)      | 0.530   | 0.54 (0.44, 0.68)      | 0.000   |
| **Duration of clopidogrel (year)** |             |         |                        |         |
| <1                         | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 1–2                        | 3.67 (2.07, 6.52)      | <0.001  | 2.06 (1.15, 3.68)      | 0.010   |
| 2–3                        | 2.66 (1.37, 5.15)      | <0.001  | 1.20 (0.61, 2.35)      | 0.610   |
| **Duration of dual agents (year)** |               |         |                        |         |
| <1                         | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 1–2                        | 19.89 (12.81, 30.87)   | <0.001  | 8.07 (5.15, 12.64)     | <0.001  |
| 2–3                        | 11.56 (7.88, 16.96)    | <0.001  | 4.89 (3.30, 7.24)      | <0.001  |
| ≥3                         | 0.95 (0.77, 1.17)      | 0.630   | 0.50 (0.40, 0.62)      | <0.001  |

cSHR: crude subhazard ratio; aSHR: adjusted subhazard ratio; 95% CI: 95% confidence interval; cDDD: cumulative daily defined dose.

Table 5 demonstrates the risk of hemorrhagic stroke stratified by dosage and duration of the use of antiplatelet agents. Antiplatelet agents did not increase the risk of hemorrhagic stroke in any range of dosage and duration.

### Table 5. The hazard ratio of hemorrhagic stroke among patients taking antiplatelet agents.

| Variables                  | cHR (95% CI)          | p-Value | aHR (95% CI)          | p-Value |
|----------------------------|------------------------|---------|------------------------|---------|
| **Aspirin or clopidogrel** |                        |         |                        |         |
| Non-users                  | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| users                      | 0.83 (0.45, 1.55)      | 0.558   | 0.8 (0.43, 1.49)       | 0.479   |
| **Aspirin or clopidogrel** |                        |         |                        |         |
| Non-users                  | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| Aspirin monotherapy        | 0.57 (0.26, 1.25)      | 0.162   | 0.63 (0.29, 1.38)      | 0.250   |
| Clopidogrel monotherapy    | 1.83 (0.44, 7.5)       | 0.404   | 0.91 (0.22, 3.81)      | 0.903   |
| Dual Therapy               | 2.72 (0.85, 8.68)      | 0.091   | 1.74 (0.54, 5.62)      | 0.353   |
| **Dose of aspirin**        |                        |         |                        |         |
| <28 cDDD                   | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 28–179 cDDD                | 0.80 (0.38, 1.68)      | 0.561   | 0.92 (0.44, 1.93)      | 0.828   |
| 180–359 cDDD               | 0.65 (0.09, 4.68)      | 0.668   | 0.67 (0.09, 4.85)      | 0.692   |
| >360 cDDD                  |                        |         |                        |         |
| **Dose of clopidogrel**    |                        |         |                        |         |
| <28 cDDD                   | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 28–179 cDDD                | 3.22 (0.79, 13.16)     | 0.103   | 1.74 (0.42, 7.18)      | 0.446   |
| 180–359 cDDD               | 4.30 (1.05, 17.61)     | 0.042   | 2.61 (0.63, 10.82)     | 0.187   |
| >360 cDDD                  |                        |         |                        |         |
| **Dose of dual agents**    |                        |         |                        |         |
| <28 cDDD                   | 1.00 (reference)       | 1.00    | 1.00 (reference)       | 1.00    |
| 28–179 cDDD                | 0.80 (0.38, 1.68)      | 0.559   | 0.86 (0.41, 1.8)       | 0.688   |
Table 5. Cont.

| Variables                          | Hemorrhagic Stroke |
|------------------------------------|--------------------|
|                                    | cHR (95% CI)       | p-Value | aHR (95% CI)   | p-Value |
| 180–359 cDDD                       | 2.08 (0.76, 5.74)  | 0.155   | 1.81 (0.66, 5) | 0.253   |
| >360 cDDD                          |                    |         |                |         |
| Duration of aspirin (year)         |                    |         |                |         |
| <1                                 | 1.00 (reference)   |         | 1.00 (reference)|         |
| 1–2                                | 0.50 (0.07, 3.58)  | 0.488   | 0.55 (0.08, 3.95)| 0.550   |
| ≥2                                 | 0.65 (0.2, 2.06)   | 0.461   | 0.78 (0.24, 2.48)| 0.669   |
| Duration of clopidogrel (year)     |                    |         |                |         |
| <1                                 | 1.00 (reference)   |         | 1.00 (reference)|         |
| 1–2                                |                    |         |                |         |
| ≥2                                 |                    |         |                |         |
| Duration of dual agents (year)     |                    |         |                |         |
| <1                                 | 1.00 (reference)   |         | 1.00 (reference)|         |
| 1–2                                | 0.42 (0.06, 3.04)  | 0.392   | 0.39 (0.05, 2.83)| 0.353   |
| ≥2                                 | 0.53 (0.17, 1.7)   | 0.290   | 0.54 (0.17, 1.73)| 0.303   |

CI: 95% confidence interval; cDDD: cumulative daily defined dose.

4. Discussion

In our study, we showed that lower exposure (28–179 cDDD, 1–2 years) to antiplatelet agents could not exert protective effects (or even detrimental) to the hip fracture. The best regimen to fend off the hip fracture was the use of aspirin and clopidogrel for ≥3 years. As for the risk of major bleeding, antiplatelet agents did not increase the risk of hemorrhagic stroke in any range of dosage and duration. These results have not been published before and merit noticing.

Aspirin has multiple mechanisms of action including effects on prostaglandin production and nitric oxide (NO) and NF-κB production, all of them may affect bone metabolism [15]. The mechanism by which aspirin facilitates bone anabolism is through irreversible inhibition of cyclooxygenase (COX) [16]. Bauer et al. evaluated the risk factors for osteoporosis and the exposure to aspirin and NSAIDs in 7786 Caucasian women over 65 years of age for 4 years. The authors showed that regular administration of aspirin or NSAIDs may exert mild increments in bone mineral density (BMD) among postmenopausal females. This phenomenon persists after adjustment for the presence of osteoarthritis and obesity. However, among the females who take aspirin or NSAIDs regularly, there is no significant risk-reduction effects on the subsequent fractures [17]. In another study, NSAID and aspirin use and BMD were assessed in 2853 adults (49.5% women, 50.5% men; mean age: 73.6 years). After adjustment for pertinent confounders, current exposure to COX-2 selective NSAIDs with aspirin was correlated with higher BMD at the whole body (4.2%), and total hip (4.6%) by dual-energy X-ray absorptiometry and at both cortical spine (12.8%) and trabecular (34.1%) by quantitative computed tomography. The authors thus concluded that the combination of relative COX-2 selective NSAIDs and aspirin is associated with higher BMD at multiple skeletal sites in men and women [15]. These studies suggested the potential protective effects of aspirin [15,17]. On the contrary, one Danish study showed that low-dose aspirin is correlated with higher susceptibility to overall fractures and hip fractures, and clopidogrel is not correlated with increased fracture risk [18]. The authors tried to explain these seemingly conflicting findings by the fact that this study only focused on low doses of aspirin prescribed for the prophylaxis of thromboembolic complications while the other studies focus on all dose ranges. Differences might also be present in the cohorts analyzed, especially as low dose and high dose (≥500 mg/day) aspirin are prescribed for different situations and thus the health conditions of the individuals enrolled might be of great heterogeneity. These findings suggested the importance of exposure stratification and population specification. The current publications discussing the correlation between aspirin and fracture are summarized in Table 6.
Table 6. Characteristics of publications discussing the correlation between aspirin and fracture.

| Design | Population Characteristics | Aspirin Exposure | Outcome |
|--------|-----------------------------|------------------|---------|
| Bauer et al. (1996) [17] | Cohort | 7786 US white women ≥ age 65 | <1, 1–4, 5–7 use/week for 3.9 years | In age-adjusted analyses, daily use of aspirin or NSAIDs was associated with 2.3–5.8% increase in BMD of the hip and spine. The relationship persisted even after adjustment for weight, medications, and self-reported and radiographic OA (adjusted increase in BMD: 1.0–3.1%). Fracture risk was similar among daily users of aspirin and NSAIDs and nonusers. After adjustment for confounders, among daily aspirin users the relative risk of hip fracture was 1.1 (95% CI: 0.7, 1.6), and among daily NSAID users the risk was 0.9 (CI: 0.6, 1.4). The risk among aspirin users was 1.0 (CI: 0.8, 1.2), and among NSAID users the risk was also 1.0 (CI: 0.8, 1.2) for all non-spine fractures. |
| Carbone et al. (2003) [15] | CS | 70–79 years of age, no difficulty in walking one-quarter mile, climbing 10 stairs without resting. A total of 3075 subjects were enrolled from Memphis, Tennessee (n = 1548), and Pittsburgh, Pennsylvania (n = 1527). | 328 ± 302 mg/day | After adjustment for confounders, current use of COX-2 NSAIDs with aspirin was associated with higher BMD at the whole body (4.2%, 1.2–7.3 CI) and total hip (4.6%, 0.5–8.8 CI) by DXA and at both trabecular (34.1%, 15.4–52.7 CI) and cortical spine (12.8%, 2.3–23.3 CI) by qCT. |
| Vestergaard et al. (2006) [19] | CC | Danish population-based study, recruiting 124,655 fractures in year 2000. For each case, 3 controls (n = 373,962) matched on age and sex were randomly drawn from the background population. | <20, 20–74, >75 cDDD | For acetaminophen, a small increase in overall fracture risk was observed with use within the last year (OR = 1.45, 95% CI: 1.41–1.49). For aspirin, no increase in overall fracture risk was present with recent use. Significant heterogeneity was present for the NSAIDs; e.g., ibuprofen was associated with an increased overall fracture risk (OR = 2.09, 95% CI: 2.00–2.18 for <20 cDDD), while celecoxib was not (OR = 0.76, 95% CI: 0.51–1.13 for <20 cDDD). Osteoarthritis was associated with a decreased risk of any fracture if diagnosed > 1 year ago (OR = 0.70, 95% CI: 0.67–0.72). |
| Hill et al. (2008) [20] | CS | 2501 men aged 40 to 93 years were recruited from the Caribbean Island of Tobago. | Self-report of use ≥ 3 times per week. | BMD was 10% and 20% higher in African Caribbean males compared to U.S. non-Hispanic black and white males, respectively. Greater lean mass, history of working on a fishing boat or on a farm, frequent walking, and self-reported diabetes were associated with higher BMD. Fat mass, history of farming, and self-reported hypertension were associated with higher BMAD. Older age, mixed African ancestry, and history of a fracture were associated with lower BMD and BMAD. Lean body mass explained 20%, 18%, and 6% of the variance in BMD at the total hip, femoral neck, and BMAD, respectively. |
### Table 6. Cont.

| Design Population Characteristics | Aspirin Exposure | Outcome |
|-----------------------------------|-----------------|---------|
| Vestergaard et al. (2012) [18]    | ≤150 mg/day     | Fracture Use of low-dose aspirin was actually associated to a small decrease in fracture risk (OR = 0.93, 95% CI: 0.91–0.96). |
| Between 2008 and 2012, information on medication use and DXA measured vertebral and femoral BMD of 916 participants was collected in the Netherlands Epidemiology of Obesity study. A subgroup analysis in postmenopausal women (n = 329) was conducted | 30–125 mg for ≥1 year | BMD After adjustment, there was no difference between aspirin users and non-users for vertebral BMD (adjusted mean difference: 0.036 (95% CI −0.027 to 0.100) g/cm²) and femoral BMD (adjusted mean difference: 0.001 (−0.067 to 0.069) g/cm²). In the subgroup of postmenopausal women, aspirin use was not associated with lower vertebral (adjusted mean difference: 0.069 (−0.046 to 0.184) g/cm²) or femoral BMD (adjusted mean difference: −0.055 (−0.139; 0.029) g/cm²). |

CC: case-control; CS: cross-sectional; BMD: bone mineral density; DXA: dual-energy X-ray absorptiometry; NSAID: non-steroid anti-inflammatory drugs; CI: confidence interval; qCT: quantitative computed tomography; OR: odds ratio; BMAD: bone mineral apparent density (volumetric BMD); cDDD: cumulative defined daily dose.

Clopidogrel is a thienopyridine and could irreversibly inhibit the P2Y12 ADP receptor [5]. Both osteoblast and osteoclast possess P2Y12 ADP receptor. Xinming Su et al. showed that mice lacking P2Y12 ADP receptor had decreased osteoclast activity, and P2Y12 knock-out mice were partially protected from pathologic osteolysis associated with increased extracellular ADP [22]. However, clopidogrel also slowed proliferation and viability of osteoblasts [23]. Since clopidogrel inhibits both osteoblast and osteoclast, its final impact on bone metabolism would depend on the differential inhibitory extent. Jørgensen et al. investigated the association between clopidogrel use and fracture incidence in a Danish nationwide cohort study. All patients prescribed with clopidogrel during 1996–2008 were included (n = 77,503), and 3 nonusers were randomly matched for age and sex (n = 232,510) to each clopidogrel-treated subject. Treatment with clopidogrel was associated with increased overall and osteoporotic fracture risk, especially in subjects with a treatment duration > 1 year. However, individuals with low exposure to clopidogrel (<0.01 defined daily dose) had a lower risk of fracture than never users. The authors thus conclude that use of clopidogrel is associated with risk of fractures [4]. The same author group narrowed down the population to stroke patients. After adjusting for multiple confounders, the exposure to clopidogrel was not correlated with increased fracture risk among individuals with transient ischemic attack (TIA) or ischemic stroke. However, after adjusting for pertinent confounders, the exposure to clopidogrel was correlated with a 10–35% reduction in fracture risk [24]. The publications from the same author group exhibited seemingly contradictory results highlight the importance of sample population specification and the stratification based upon exposure (Table 7). The decreased and increased fracture risk among patients with high and low exposure to clopidogrel might be explained by the differential extent of suppression to osteoblast and osteoclast in differential exposure level to clopidogrel.
Table 7. Characteristics of publications discussing the correlation between clopidogrel and fracture.

| Design  | Population Characteristics | Clopidogrel Exposure | Outcome |
|---------|---------------------------|----------------------|---------|
| Jorgensen et al. (2012) [5] | Cohort 77,503 clopidogrel users between 1996 and 2008 in Denmark were recruited, and 232,510 non-users were randomly matched by age and sex as controls. | <0.10, 0.10–0.39, 0.40–0.99, ≥1 DDD | Fracture For clopidogrel, both increased risk of overall fracture and osteoporotic fractures were present, especially in treatment duration of more than 1 year. However, individuals with low exposure to clopidogrel (≤0.01 DDD) had a lower risk of fracture than never users. |
| Jorgensen et al. (2017) [24] | Cohort 77,503 clopidogrel users between 1996 and 2008 in Denmark were recruited, and 232,510 non-users were randomly matched by age and sex as controls. The study end-points were occurrence of stroke, TIA, and occurrence of fracture. | <0.10, 0.10–0.39, 0.40–0.79, ≥0.8 DDD | Fracture After adjusting for multiple confounders, clopidogrel use was not associated with increased fracture risk in subjects with ischemic stroke or TIA. In contrast, after adjusting for multiple confounders clopidogrel treatment was associated with a 10–35% reduced risk of fracture |

DDD: daily defined dose; TIA: transient ischemic attack.

The inconclusive findings from previous publications may be explained by the different population and different exposure stratification. In view of the unaddressed issues of previous works, our study narrowed down our sample population to T2DM patients, and rigorous stratification based upon dose and duration was performed. Moreover, we specify the dual agent using population from the single agent using population following the analytic protocol of our previous works [12]. These endeavors substantially supplement our understanding about the impact of antiplatelet agents on bone health among T2DM patients.

There are some limitations in our study. First, the study is retrospective in nature and randomized control trial may be needed in the future. However, aspirin and clopidogrel are one of the standard treatments for several chronic disease with proven benefits, so it would have ethical problem to include controlled group in population. Second, despite many confounding factors were adjusted in our study, there were still other confounding factors not included that may influence the results, such as the serum 25-(OH)-D level and bone densiometric findings. In other words, it is impossible to include all the confounders in our model. Moreover, our study was performed in the Taiwanese ethnic group, and these findings should be extrapolated to other ethnic groups (such as Caucasians) with due caution. To draw a general conclusion about the impacts of antiplatelet agents on bone health without the overall fractures data indeed limits the validity and generalizability of the conclusions. The reason we investigate hip fracture only is because some osteoporotic fractures, such as proximal humerus fractures and distal radius fractures, might not be accurately coded if the patients did not chose surgical treatment.

However, our study bears some strengths which deserve noticing. We clearly offered the rigorous stratification of the duration and dosage of aspirin, clopidogrel, and dual agents, demonstrating the differential association between the risk of hip fracture and the exposure of antiplatelet agents. We highlighted the group of combined aspirin and clopidogrel, demonstrating that the stratification associated with the lowest risk of hip fracture was the use of aspirin and clopidogrel for ≥3 years. We also investigated the risk of hemorrhagic stroke among T2DM patients under antiplatelet therapy. These findings help clinicians balance between the risk of hip fracture and the risk of bleeding-related morbidities when prescribing antiplatelet agents.
5. Conclusions

According to our study, only higher dosage (>360 cDDD) as well as longer duration of (≥ 3 years) antiplatelet agents could be associated with lower risk of hip fracture. Lower dosage (28–179 cDDD) and shorter duration (1~2 years) could even be associated with higher fracture risk.

Author Contributions: Conceptualization, S.-H.C. and S.-J.K.; software, J.-N.L. and C.-Y.H.; methodology, H.-T.Y.; validation, J.-T.M. and Y.-H.F.; formal analysis, H.-T.Y. and Y.-C.L.; investigation, S.-J.K.; resources, J.-N.L.; data curation, Y.-H.F. and H.-T.Y.; writing—original draft preparation, J.-T.M. and Y.-C.L.; writing—review and editing, S.-H.C. and S.-J.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Health and Welfare Clinical Trial Center, Taiwan (MOHW109-TDU-B-212-114004), the Minister of Science and Technology, Taiwan (109-2314-B-039-018-MY3, 108-2622-E-039-002-CC1, 109-2321-B-039-002, and 108-2221-E-039-006-MY3), China Medical University (CMU109-MF-82), and China Medical University Hospital (DMR-110-111, DMR-110-222, DMR-110-224, DMR-111-114, and DMR-111-230), and Tseng-Lien Lin Foundation, Taichung, Taiwan.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of China Medical University and Hospital (CMUH104-REC2-115 (CR4), date of approval: 5 July 2019).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res. Clin. Pract.* 2010, 87, 4–14. [CrossRef] [PubMed]
2. Tebe, C.; Martínez-Laguna, D.; Carbonell-Abella, C.; Reyes, C.; Moreno, V.; Diez-Perez, A.; Collins, G.S.; Prieto-Alhambra, D. The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: A multi-state cohort analysis. *Osteoporos Int.* 2019, 30, 2407–2415. [CrossRef] [PubMed]
3. Franceschi, C.; Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J. Gerontol. A Biol. Sci. Med. Sci.* 2014, 69 (Suppl. S1), S4–S9. [CrossRef] [PubMed]
4. Buckley, K.A.; Golding, S.L.; Rice, J.M.; Dillon, J.P.; Gallagher, J.A. Release and interconversion of P2 receptor agonists by human osteoblast-like cells. *FASEB J.* 2003, 17, 1401–1410. [CrossRef] [PubMed]
5. Jorgensen, N.R.; Grove, E.L.; Schwarz, P.; Vestergaard, P. Clopidogrel and the risk of osteoporotic fractures: A nationwide cohort study. *J. Intern Med.* 2012, 272, 385–393. [CrossRef] [PubMed]
6. Hsu, C.C.; Ko, J.Y.; Lin, C.L.; Hsu, H.C.; Chen, H.T.; Lin, C.C.; Kuo, S.J. The Epidemiology of Hip Fracture among Subjects with Pyogenic Liver Abscess (PLA): A Nationwide Population-Based Study. *BioMed Res. Int.* 2020, 2020, 5901962. [CrossRef]
7. Hsu, C.C.; Hsu, H.C.; Lin, C.C.; Wang, Y.C.; Chen, H.J.; Chiu, Y.C.; Chang, C.C.; Kuo, S.J. Increased Risk for Hip Fractures among Patients with Cholangitis: A Nationwide Population-Based Study. *BioMed Res. Int.* 2018, 2018, 8928174. [CrossRef]
8. Lin, C.J.; Hsu, C.J.; Chen, C.H.; Yip, H.T.; Hung, T.Y.; Wang, Y.Y.; Ko, J.Y.; Kuo, S.J. The association between gallstone disease (GSD) and hip fracture: A nationwide population-based study. *Postgrad. Med. 2021*, 133, 357–361. [CrossRef]
9. Galanis, D.; Soultaonis, K.; Lelovas, P.; Zervas, A.; Papadopoulos, P.; Galanos, A.; Argyropoulou, K.; Makropoulou, M.; Patsaki, A.; Passali, C.; et al. Protective effect of Glycyrrhiza glabra roots extract on bone mineral density of ovariectomized rats. *Biomedicine 2019*, 9, 8. [CrossRef]
10. Wu, M.H.; Lee, T.H.; Lee, H.P.; Li, T.M.; Lee, I.T.; Shieh, P.C.; Tang, C.H. Kuei-Lu-Er-Xian-Jiao extract enhances BMP-2 production in osteoblasts. *Biomedicine 2017*, 7, 2. [CrossRef]
11. Barker, A.L.; Soh, S.E.; Sanders, K.M.; Pasco, J.; Khosla, S.; Ebeling, P.R.; Ward, S.A.; Peeters, G.; Talevska, J.; Cumming, R.G.; et al. Aspirin and fracture risk: A systematic review and exploratory meta-analysis of observational studies. *BMJ Open 2020*, 10, e026876. [CrossRef] [PubMed]
12. Kuan, Y.C.; Huang, K.W.; Lin, C.L.; Luo, J.C.; Kao, C.H. Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus. *Cancers 2019*, 11, 1468. [CrossRef] [PubMed]
13. Lai, S.W.; Liao, K.F.; Lin, C.L.; Lin, C.H. Association between Parkinson’s disease and proton pump inhibitors therapy in older people. *Biomedicine 2020*, 10, 1–4. [CrossRef] [PubMed]
14. Lai, S.W.; Liao, K.F.; Lin, C.L.; Lin, C.C.; Lin, C.H. Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013. Biomedicine 2020, 10, 1–4. [CrossRef] [PubMed]

15. Carbone, L.D.; Tylavsky, F.A.; Cauley, J.A.; Harris, T.B.; Lang, T.F.; Bauer, D.C.; Barrow, K.D.; Kritchevsky, S.B. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: Impact of cyclooxygenase selectivity. J. Bone Miner. Res. 2003, 18, 1795–1802. [CrossRef] [PubMed]

16. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231, 232–235. [CrossRef]

17. Bauer, D.C.; Orwoll, E.S.; Fox, K.M.; Vogt, T.M.; Lane, N.E.; Hochberg, M.C.; Stone, K.; Nevitt, M.C. Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 1996, 11, 29–35. [CrossRef]

18. Vestergaard, P.; Steinberg, T.H.; Schwarz, P.; Jørgensen, N.R. Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int. J. Cardiol. 2012, 160, 36–40. [CrossRef]

19. Vestergaard, P.; Rejnmark, L.; Mosekilde, L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif. Tissue Int. 2006, 79, 84–94. [CrossRef]

20. Hill, D.D.; Cauley, J.A.; Sheu, Y.; Bunker, C.H.; Patrick, A.L.; Baker, C.E.; Beckles, G.L.; Wheeler, V.W.; Zmuda, J.M. Correlates of bone mineral density in men of African ancestry: The Tobago bone health study. Osteoporos Int. 2008, 19, 227–234. [CrossRef]

21. Bonten, T.N.; de Mutsert, R.; Rosendaal, F.R.; Jukema, J.W.; van der Bom, J.G.; de Jongh, R.T.; den Heijer, M. Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. Int. J. Cardiol. 2017, 244, 298–302. [CrossRef] [PubMed]

22. Su, X.; Floyd, D.H.; Hughes, A.; Xiang, J.; Schneider, J.G.; Uluckan, O.; Heller, E.; Deng, H.; Zou, W.; Craft, C.S.; et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J. Clin. Investig. 2012, 122, 3579–3592. [CrossRef] [PubMed]

23. Syberg, S.; Brandao-Burch, A.; Patel, J.J.; Hajjawi, M.; Arnett, T.R.; Schwarz, P.; Jørgensen, N.R.; Orriss, I.R. Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J. Bone Miner. Res. 2012, 27, 2373–2386. [CrossRef] [PubMed]

24. Jørgensen, N.R.; Schwarz, P.; Iversen, H.K.; Vestergaard, P. P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients. Front. Pharmacol. 2017, 8, 821. [CrossRef]